Home › Research › Drug development
Re: Aducanumab-Related ARIA: Paean or Lament?
Wassef HR, Colletti PM.. Clinical nuclear medicine, 2022-11-11
Topic: Amyloid, tau and blood-test diagnosis
Abstract Høilund-Carlsen and colleagues raise concern regarding the reliability of amyloid PET to exclude Alzheimer disease. We present additional studies of amyloid PET and discuss the diagnostic challenges in Alzheimer disease. We discuss the limitations of amyloid in diagnosis and evaluation of therapy response in AD.
Key findings
- We present additional studies of amyloid PET and discuss the diagnostic challenges in Alzheimer disease.
- We discuss the limitations of amyloid in diagnosis and evaluation of therapy response in AD.
Why it matters
This reply discusses the diagnostic challenges in Alzheimer disease and the limitations of amyloid in diagnosis and in evaluating therapy response. It presents additional studies of amyloid PET but reports no treatment or cure.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 30 of the 94 points we could judge it on, which is 32 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical nuclear medicine) |
| Journal's citation record | 1 / 4 | Clinical Nuclear Medicine: journal h-index 90 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Patrick M. Colletti: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36607365) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 30 of the 94 points we could judge it on is 32 out of 100. |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Wassef, H. R., & Colletti, P. M. (2023). Re: Aducanumab-Related ARIA: Paean or Lament? Clinical nuclear medicine. https://doi.org/10.1097/rlu.0000000000004490
Vancouver
Wassef HR, Colletti PM. Re: Aducanumab-Related ARIA: Paean or Lament? Clinical nuclear medicine. 2023. doi:10.1097/rlu.0000000000004490. PMID: 36607365.
BibTeX
@article{wassef2023-36607365,
author = {Wassef, H. R. and Colletti, P. M.},
title = {{Re: Aducanumab-Related ARIA: Paean or Lament?}},
journal = {Clinical nuclear medicine},
year = {2023},
doi = {10.1097/rlu.0000000000004490},
pmid = {36607365},
url = {https://doi.org/10.1097/rlu.0000000000004490}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development
Also in Drug development
79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.